the Republic of Moldova will add vaccination against human papillomavirus (HPV) to the routine immunization schedule

Moldova (Republic Of)
NITAGs
6 February 2017

Vaccination against human papillomavirus (HPV) will be added to the routine immunization schedule in the Republic of Moldova in November 2017. Timely vaccination against HPV prevents infection with viruses that are the leading cause of cervical and other cancers. The Ministry of Health’s decision to introduce the vaccine followed the recommendation of the country’s independent national immunization technical advisory committee (NITAG) based on its thorough review of available evidence. 

Flag_of_Moldova.svg.png

WHO/Europe support for the decision-making process has included organization of a national conference and stakeholders’ meeting on HPV disease and vaccines on 29–30 September 2016 in Chisinau, Republic of Moldova. The conference brought together public health professionals and clinicians (obstetricians/gynaecologists, paediatricians, oncologists), medical academia, Ministry of Health officials, representatives of the Medical and Pharmaceutical State University, the national immunization programme, United Nations agencies and other stakeholders. They discussed the burden of cervical cancer in the Republic of Moldova and the experience of countries globally and in the European Region in implementing the HPV vaccine, including country efforts to address vaccine safety concerns, as well as other challenges and lessons learnt.

Burden of HPV-related disease

HPV poses a serious burden on public health in the Republic of Moldova. According to WHO estimates, HPV caused cervical cancer in more than 470 women and was responsible for 210 deaths in the country in 2012 alone. Cervical cancer is the third most prevalent of all cancers among women. The Republic of Moldova is among the top 5 countries in the WHO European Region with the highest cervical cancer mortality rates. The introduction of HPV vaccine along with implementation of other preventive interventions will help significantly reduce morbidity and mortality owing to cervical cancer and other HPV-related conditions.
By 2016, 28 countries of the WHO European Region and 67 countries globally introduced HPV vaccine into routine immunization programmes; and after 10 years and more than 200 million doses used, there is strong evidence to support that HPV vaccine is effective and safe. The successful introduction of HPV vaccine requires implementation of intensified public awareness activities and active involvement of health workers.

Related News & Events

  • Mali
    NITAGs

    The Ministry of Health of Mali designates the NITAG members

    04.09.2018

    In 2014 the Ministry of Public Health and Hygiene of Mali signed a decree to establish the NITAG. Four years later, the Ministry of Health nominates the 13 core members as well as the ex-officio and liaision members.

    Read more
  • United Kingdom
    NITAGs

    JCVI recommends to extend vaccination against HPV to boys

    18.07.2018

    The Joint Committee on Vaccination and Immunisations (JCVI) has recommended that the HPV immunisation programme should be extended to cover boys.

    Read more
  • Ghana
    NITAGs

    Ghana inaugurates the NITAG

    11.07.2018

    On 16th May 2018, the Honorable minister of Health inaugurated NITAG-Ghana at the MoH conference room. Thus, Ghana took a bold step to join GAVI-eligible countries in sub-Saharan Africa to establish a National Immunization Technical Advisory Group (NITAG).

     

    Read more